All In MedTech

Device Trial Radar · NCT07089576

Clinical Study to Evaluate the Safety and Effectiveness of Arcevo LSA

A Prospective, Multi-center Clinical Study to Evaluate the Safety and Effectiveness of Arcevo LSA in the Open Repair of Aortic Arch Aneurysms and Dissections

Last checked: Nov 20, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

132

Planned (sponsor's estimate)

Start

Nov 4, 2025

Primary completion

Apr 2028

Study completion Jul 2032

Sponsor

Lead sponsor
Artivion Inc.Public (AORT)
Sponsor type
Industry
Collaborators
Bright Research Partners
First posted
Jul 28, 2025

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if the Arcevo LSA stent graft can safely and effectively treat patients that have an acute or chronic aortic dissection and/or aneurysm that involves the aortic arch and the descending thoracic aorta, with or without the involvement of the ascending aorta.

Conditions

  • Aortic Arch Aneurysm
  • Aortic Arch Dissection
  • Chronic Aortic Dissection
  • Acute Aortic Dissection

Interventions

  • Arcevo™ LSA Hybrid Stent Graft SystemDevice

    The Arcevo LSA Hybrid Stent Graft System is an implantable aortic stent graft with LSA branch which is preloaded onto a delivery system and implanted during an open surgical procedure, or more specifically a total arch replacement procedure. The device is intended for use with a proximal surgical graft (not supplied). If additional coverage is needed, a protocol specified thoracic endovascular aortic repair (TEVAR) device may be used.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Composite Rate of Patients Free From ≥1 Major Adverse EventTime frame: 1 year post-index procedure of LSA stent graft implant

Locations

26 sites in 3 countries. Site status is shown where the registry gives one.

  • University of Alabama

    Birmingham, Alabama · Recruiting

25 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.